{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:20:40Z","timestamp":1784755240889,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The use of immunosuppressive drugs for vitiligo treatment carries a potential risk of increased infection, whereas IFN\u03b3 bispecific antibodies represent an alternative therapeutic strategy. Researchers employing the melanoma\/Treg vitiligo mouse model identified a critical role of dermal fibroblasts during the progressive phase of vitiligo. These fibroblasts respond to IFN\u03b3 and recruit CD8\u202f+\u202fT cells, a mechanism that also contributes to the bilateral symmetrical depigmentation commonly observed in vitiligo patients. To evaluate the suitability of this model as a platform for developing fibroblast-targeted IFN\u03b3 bispecific antibodies, mice were administered regular injections of IFN\u03b3 monoclonal antibodies. The IFN\u03b3 monoclonal antibody treatment significantly suppressed vitiligo progression in the melanoma\/Treg model. Owing to its advantages\u2014including straightforward induction, multi-antigen specificity, and the demonstrated efficacy of IFN\u03b3 blocking antibodies, the melanoma\/Treg vitiligo mouse model is a robust platform for advancing the development of fibroblast-targeted IFN\u03b3 bispecific antibodies.<\/jats:p>","DOI":"10.3389\/fmed.2025.1677626","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:31:57Z","timestamp":1758864717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The fibroblast-driven melanoma\/Treg vitiligo mouse model is effectively suppressed by IFN\u03b3 blocking antibody"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuhua","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/J.Jid.2022.05.1093","article-title":"Addition of narrow-b and Uvb phototherapy to Ruxolitinib cream in patients with vitiligo","volume":"142","author":"Pandya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/Ced.14435","article-title":"Vitiligo: an update on systemic treatments","volume":"46","author":"Searle","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/S40259-023-00612-7","article-title":"The emerging safety profile of Jak inhibitors in rheumatic diseases","volume":"37","author":"Singh","year":"2023","journal-title":"BioDrugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/Annrheumdis-2023-Eular.6317","article-title":"Ab0501 analysis of adverse effects in immune-mediated inflammatory diseases treated with Jak inhibitors in a single center","volume":"82","author":"Pineiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1134\/S0026893318020176","article-title":"Bispecific antibodies: formats and areas of application","volume":"52","author":"Vasilenko","year":"2018","journal-title":"Mol Biol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/S10238-024-01520-Y","article-title":"Bispecific antibodies in clinical practice: understanding recent advances and current place in Cancer treatment landscape","volume":"25","author":"Verma","year":"2024","journal-title":"Clin Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.4049\/Jimmunol.0902778","article-title":"Mechanisms of spatial and temporal development of autoimmune vitiligo in Tyrosinase-specific Tcr transgenic mice","volume":"184","author":"Gregg","year":"2010","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/Jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires Ifn-\u0393 for autoreactive Cd8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/Jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J Invest Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"223ra223","DOI":"10.1126\/Scitranslmed.3007811","article-title":"Cxcl10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/S41467-019-09963-8","article-title":"Innate lymphocyte-induced Cxcr3b-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/J.Jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/J.Jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1016\/J.Jid.2022.06.007","article-title":"A Keratinocyte-tethered biologic enables location-precise treatment in mouse vitiligo","volume":"142","author":"Hsueh","year":"2022","journal-title":"J Invest Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/S41586-021-04221-8","article-title":"Anatomically distinct fibroblast subsets determine skin autoimmune patterns","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/S13619-022-00132-9","article-title":"A mouse model of vitiligo based on endogenous auto-reactive Cd8\u202f+\u202fT cell targeting skin melanocyte","volume":"11","author":"Chen","year":"2022","journal-title":"Cell Regen"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/S41598-018-19407-W","article-title":"Pd-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"E486","DOI":"10.1016\/J.Stem.2018.07.016","article-title":"Hoxc-dependent mesenchymal niche heterogeneity drives regional hair follicle regeneration","volume":"23","author":"Yu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/Pnas.1614775114","article-title":"Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model","volume":"114","author":"Wu","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"174ra128","DOI":"10.1126\/Scitranslmed.3005127","article-title":"Mutant Hsp70 Reverses Autoimmune Depigmentation In Vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci Transl Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"Eadl","DOI":"10.1126\/Science.Adl2016","article-title":"Interferon-\u0393 And infectious diseases: lessons And prospects","volume":"384","author":"Casanova","year":"2016","journal-title":"Science"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in Ifn-\u0393 signaling And response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1677626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:31:58Z","timestamp":1758864718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1677626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":22,"alternative-id":["10.3389\/fmed.2025.1677626"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1677626","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1677626"}}